4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001549595-24-000008
Chief Scientific Officer sold 2,334 shares at $7.99 ($18,649)
- Chief Scientific Officer acquired 5,207 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-01-30 | Exercise or conversion : show line 1 in the form | +3,207 | 36,736 | D | ||
| 2024-01-30 | Exercise or conversion : show line 2 in the form | +2,000 | 38,736 | D | ||
| 2024-01-30 | Sale : show line 3 in the form | −2,334 | $7.99 | $18,649 | 36,402 | D |
| Open-market sales · 2,334 sh · avg $7.99 · $18,649 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-01-30 | Exercise or conversion : show line 4 in the form Restricted Stock Units | −3,207 | 25,654 | D |
| 2024-01-30 | Exercise or conversion : show line 5 in the form Restricted Stock Units | −2,000 | 18,000 | D |
Loading xslF345X05/wk-form4_1706658767.xml…